Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21506203 | 0.86 | KDM4E (0.37) | CHRM5ADRA2CPIK3CDMEN1KMT2A | |
| SCHEMBL24765448 | 0.82 | PIK3CD (0.42) | CHRM5ADRA2CPIK3CDKMT2AALDH1A1 | |
| SCHEMBL19228200 | 0.82 | PIK3CD (0.37) | CHRM5ADRA2CPIK3CDMEN1KMT2A | |
| SCHEMBL23386418 | 0.81 | CHRM5 (0.36) | CHRM5ADRA2CPIK3CDMEN1KMT2A | |
| SCHEMBL22020562 | 0.81 | CYP3A4 (0.35) | CHRM5ADRA2CKDM4EACHECYP1A2 | |
| SCHEMBL9925435 | 0.81 | CYP3A4 (0.35) | CHRM5ADRA2CKDM4EACHECYP1A2 | |
| SCHEMBL18427493 | 0.81 | PIK3CD (0.41) | CHRM5ADRA2CPIK3CDKMT2AKDM4E | |
| SCHEMBL12436 | 0.81 | PIK3CD (0.41) | CHRM5ADRA2CPIK3CDKMT2AKDM4E | |
| SCHEMBL20078738 | 0.81 | CHRM5 (0.37) | CHRM5ADRA2CPIK3CDMEN1KMT2A | |
| SCHEMBL21864494 | 0.80 | KDM4E (0.56) | CHRM5ADRA2CPIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | CHRM5 4779/4885ADRA2C 4478/4885PIK3CD 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.